Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment

JAMA Psychiatry

Volumn 70, Issue 9, 2013, Pages 921-930

  Blasi, Giuseppe ^a   De Virgilio, Caterina ^a   Papazacharias, Apostolos ^a   Taurisano, Paolo ^a   Gelao, Barbara ^a   Fazio, Leonardo ^a   Ursini, Gianluca ^a   Sinibaldi, Lorenzo ^b   Andriola, Ileana ^a   Masellis, Rita ^a   Romano, Raffaella ^a   Rampino, Antonio ^a   Di Giorgio, Annabella ^b   Lo Bianco, Luciana ^a,c   Caforio, Grazia ^a   Piva, Francesco ^c   Popolizio, Teresa ^b   Bellantuono, Cesario ^c   Todarello, Orlando ^a   Kleinman, Joel E ^d   Gadaleta, Gemma ^a   Weinberger, Daniel R ^e   Bertolino, Alessandro ^a   more..

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OLANZAPINE; SEROTONIN 2A RECEPTOR;

ALLELE; ARTICLE; ATTENTION; AUTOPSY; BEHAVIOR; BOLD SIGNAL; CASE CONTROL STUDY; COMPUTER MODEL; CONTROL; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGATIVE SYNDROME; PHENOTYPE; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RNA SPLICING; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; WORKING MEMORY;

EID: 84883538421     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.1378     Document Type: Article

References (82)

1. Buhot MC. Serotonin receptors in cognitive behaviors. Curr Opin Neurobiol. 1997;7(2):243-254.
2. Fink KB, Göthert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev. 2007;59(4):360-417.
3. Puig MV, Watakabe A, Ushimaru M, Yamamori T, Kawaguchi Y. Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors. J Neurosci. 2010;30(6):2211-2222.
4. Jakab RL, Goldman-Rakic PS. Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex. J Comp Neurol. 2000;417(3):337-348. (Pubitemid 30080377)
5. Willins DL, Deutch AY, Roth BL. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 1997;27(1):79-82. (Pubitemid 27327604)
6. Harvey JA. Role of the serotonin 5-HT2A receptor in learning. Learn Mem. 2003;10(5):355-362.
7. Williams GV, Rao SG, Goldman-Rakic PS. The physiological role of 5-HT2A receptors in working memory. J Neurosci. 2002;22(7):2843-2854. (Pubitemid 37465833)
8. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry. 2000;57(9):907-913.
9. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol. 2007;78:133-164.
10. González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452(7183):93-97. (Pubitemid 351355090)
11. Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem. 2003;85(1):1-13.
12. Rasmussen H, Erritzoe D, Andersen R, et al. Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry. 2010;67(1):9-16.
13. González-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci. 2009;32(4):225-232.
14. Lieberman JA, Mailman RB, Duncan G, et al. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry. 1998;44(11):1099-1117. (Pubitemid 28547145)
15. Sanders AR, Duan J, Levinson DF, et al. No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry. 2008;165(4):497-506. (Pubitemid 351694293)
16. Collins AL, Kim Y, Sklar P, O'Donovan MC, Sullivan PF; International Schizophrenia Consortium. Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol Med. 2012;42(3):607-616.
17. Ayalew M, Le-Niculescu H, Levey DF, et al. Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Mol Psychiatry. 2012;17(9):887-905.
18. International HapMap Project. http://hapmap.ncbi.nlm.nih.gov/cgiperl/ gbrowse/hapmap3r2-B36/. Accessed September 30, 2012.
19. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT.Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res. 2004;67(1):53-62. (Pubitemid 38117091)
20. Zhang XN, Jiang SD, He XH, Zhang LN. 102T/C SNP in the 5-hydroxytryptamine receptor 2A (HTR2A) gene and schizophrenia in two southern Han Chinese populations: lack of association. Am J Med Genet B Neuropsychiatr Genet. 2004;126B(1):16-18.
21. Chen SF, Shen YC, Chen CH. HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients. Psychopharmacology (Berl). 2009;205(2):285-292.
22. Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, et al. Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia. Neuropsychobiology. 2011;64(4):202-210.
23. Masellis M, Basile V, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology. 1998;19(2):123-132. (Pubitemid 28288438)
24. Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry. 1998;3(1):61-66. (Pubitemid 28045186)
25. Spurlock G, Heils A, Holmans P, et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry. 1998;3(1):42-49. (Pubitemid 28045184)
26. Parsons MJ, D'Souza UM, Arranz MJ, Kerwin RW, Makoff AJ. The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry. 2004;56(6):406-410. (Pubitemid 39195320)
27. Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E. Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry. 2007;61(2):167-173. (Pubitemid 46072774)
28. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res. 2002;67(6):812-822. (Pubitemid 34226294)
29. Bray NJ, Buckland PR, Hall H, Owen MJ, O'Donovan MC. The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry. 2004;9(1):109-114. (Pubitemid 38175089)
30. Ozaki N, Rosenthal NE, Pesonen U, et al. Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls. Biol Psychiatry. 1996;40(12):1267- 1272. (Pubitemid 27006411)
31. Hazelwood LA, Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol. 2004;66(5):1293-1300. (Pubitemid 39411069)
32. Ozaki N, Manji H, Lubierman V, et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem. 1997;68(5):2186-2193. (Pubitemid 27176157)
33. Filippini N, Scassellati C, Boccardi M, et al. Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. Eur J Hum Genet. 2006;14(4):443-449.
34. Schott BH, Seidenbecher CI, Richter S, et al. Genetic variation of the serotonin 2a receptor affects hippocampal novelty processing in humans. PLoS One. 2011;6(1):e15984. doi:10.1371/journal.pone.0015984.
35. de Quervain DJ, Henke K, Aerni A, et al. A functional genetic variation of the 5-HT2a receptor affects human memory. Nat Neurosci. 2003;6(11):1141-1142. (Pubitemid 37346032)
36. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett. 1996;217(2-3):177-178. (Pubitemid 26358831)
37. Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007;14(19):2053-2069. (Pubitemid 47578163)
38. Bertolino A, Blasi G. The genetics of schizophrenia. Neuroscience. 2009;164(1):288-299.
39. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci. 2006;7(10):818-827. (Pubitemid 44435264)
40. SpliceAid: a database of strictly experimentally assessed target RNA sequences in humans. www.introni.it/splicing.html. Accessed January 10, 2011.
41. Piva F, Giulietti M, Nocchi L, Principato G. SpliceAid: a database of experimental RNA target motifs bound by splicing proteins in humans. Bioinformatics. 2009;25(9):1211-1213.
42. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol. 1997;4(3):311-323. (Pubitemid 27355870)
43. HTMseq. http://bioinfo.amc.uva.nl/HTMseq/controller. Accessed January 15, 2011.
44. Array Express. www.ebi.ac.uk/arrayexpress. Accessed January 20, 2011.
45. The Human Protein Atlas. www.proteinatlas.org/. Accessed January 22, 2011.
46. Human Protein Reference Database. www.hprd.org/. Accessed January 22, 2011.
47. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874. (Pubitemid 32447869)
48. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002;30(17):3894-3900. (Pubitemid 35012462)
49. Jpred3: a secondary structure prediction server. www.compbio.dundee.ac. uk/www-jpred. Accessed January 15, 2011.
50. The PSIPRED protein sequence analysis workbench. http://bioinf.cs.ucl.ac. uk/psipred. Accessed January 15, 2011.
51. BrainCloud. http://braincloud.jhmi.edu/. Accessed January 31, 2012.
52. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔC(T) method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
53. First MB, Gibbon M, Spitzer RL, Williams JBW. Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders - Research Version. New York, NY: Biometrics Research; 1996.
54. Blasi G, Goldberg TE, Elvevåg B, et al. Differentiating allocation of resources and conflict detection within attentional control processing. Eur J Neurosci. 2007;25(2):594-602.
55. Blasi G, Mattay VS, Bertolino A, et al. Effect of catechol-O- methyltransferase val158met genotype on attentional control. J Neurosci. 2005;25(20):5038-5045.
56. Blasi G, Taurisano P, Papazacharias A, et al. Nonlinear response of the anterior cingulate and prefrontal cortex in schizophrenia as a function of variable attentional control. Cereb Cortex. 2010;20(4):837-845.
57. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT Val 108/158Met genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;161(10):1798- 1805.
58. Statistical Parametric Mapping. SPM website. www.fil.ion.ucl.ac.uk/spm. Accessed June 6, 2013.
59. ANSIR Laboratory at Wake Forest University School of Medicine. http://fmri.wfubmc.edu/cms/software#PickAtlas. Accessed June 6, 2013.
60. Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000;22(4):518-528.
61. Bertolino A, Caforio G, Blasi G, et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res. 2007;95(1-3):253-255.
62. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res. 1996;20(3):247-252. (Pubitemid 26232968)
63. Usall J, Suarez D, Haro JM; SOHO Study Group. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153(3):225-231. (Pubitemid 47632800)
64. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994;20(1):203-214. (Pubitemid 24071103)
65. Kulkarni J, de Castella A, Fitzgerald PB, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry. 2008;65(8):955-960.
66. Liu HX, Zhang M, Krainer AR. Identification of functional exonic splicing enhancer motifs recognized by individual SR proteins. Genes Dev. 1998;12(13):1998-2012. (Pubitemid 28323874)
67. Burd CG, Dreyfuss G. RNA binding specificity of hnRNP A1: significance of hnRNP A1 high-affinity binding sites in pre-mRNA splicing. EMBO J. 1994;13(5):1197-1204. (Pubitemid 24074726)
68. Melamud E, Moult J. Structural implication of splicing stochastics. Nucleic Acids Res. 2009;37(14):4862-4872.
69. Egan MF, Goldberg TE, Gscheidle T, et al. Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry. 2001;50(2):98-107. (Pubitemid 32728209)
70. Ebdrup BH, Rasmussen H, Arnt J, Glenthøj B. Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs. 2011;20(9):1211-1223.
71. Bertolino A, Caforio G, Petruzzella V, et al. Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. Psychiatry Res. 2006;147(2-3):221-226.
72. Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res. 2003;60(2-3):285-298. (Pubitemid 36184716)
73. Normann C, Clark K. Selective modulation of Ca2+ influx pathways by 5-HT regulates synaptic long-term plasticity in the hippocampus. Brain Res. 2005;1037(1-2):187-193.
74. Maya Vetencourt JF, Sale A, Viegi A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008;320(5874):385- 388. (Pubitemid 351555663)
75. Jitsuki S, Takemoto K, Kawasaki T, et al. Serotonin mediates cross-modal reorganization of cortical circuits. Neuron. 2011;69(4):780-792.
76. Corrigan JD, Hinkeldey NS. Relationships between parts A and B of the Trail Making Test. J Clin Psychol. 1987;43(4):402-409. (Pubitemid 17107000)
77. Wingen M, Kuypers KP, Ramaekers JG. Selective verbal and spatial memory impairment after 5-HT1A and 5-HT2A receptor blockade in healthy volunteers pre-treated with an SSRI. J Psychopharmacol. 2007;21(5):477-485. (Pubitemid 47106923)
78. Gründer G, Hippius H, Carlsson A. The "atypicality" of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009;8(3):197-202.
79. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT 2A receptors by agonists and antagonists. Brain Res Bull. 2001;56(5):441-451.
80. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-246.
81. Kuoppamäki M, Pälvimäki EP, Hietala J, Syvälahti E. Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs. Neuropsychopharmacology. 1995;13(2):139-150.
82. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? a meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009;14(4):429-447.